Literature DB >> 9042622

Long-term follow-up of pulmonary function in chronic eosinophilic pneumonia. Groupe d'Etude en Pathologie Interstitielle de la Société de Pathologie Thoracique du Nord.

J Durieu1, B Wallaert, A B Tonnel.   

Abstract

The prognosis of chronic eosinophilic pneumonia (CEP) is usually good under corticosteroid therapy (CST). The main complications are relapses when treatment is tapered or discontinued. The aim of this retrospective, multicentre study was to evaluate the long-term consequences of CEP on pulmonary function tests. Nineteen patients (mean +/- SEM age 51 +/- 16 yrs) with CEP were studied. Lung function tests were performed at the time of diagnosis and at follow-up, and included flow-volume curve. The results of the first pulmonary function test were normal in six patients, restrictive in nine, and obstructive in four. Relapses (recurrence of initial signs) occurred in nine patients. The last evaluation (mean +/- SEM follow-up of 49 +/- 44 months, range 12-142 months) showed a complete recovery in 8 of the 19 patients. One patient developed bilateral apical fibrosis. The remaining 10 patients, exhibited obstructive pulmonary function without relapse of CEP at this time. Bronchoalveolar lavage (BAL) eosinophilia at the time of the initial evaluation tended to be higher (p = 0.05) in these 10 patients than in those with normal pulmonary function findings at follow-up. This study demonstrates: firstly, that the development of an obstructive ventilatory defect is a common finding during the course of chronic eosinophilic pneumonia (CEP); secondly, that bronchial obstruction might appear despite the absence of clinical and radiological signs of relapse; and, thirdly, that a markedly increased bronchoalveolar lavage eosinophilia at the initial evaluation is associated with a higher risk of development of bronchial obstruction. These results suggest that pulmonary function tests should be included in the management of chronic eosinophilic pneumonia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9042622     DOI: 10.1183/09031936.97.10020286

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

1.  Eosinophilic Lung Disease: Accompanied with 12 Cases.

Authors:  Tülin Sevim; Emine Aksoy; Fatma Tokgöz Akyıl; Meltem Çoban Ağca; Nilüfer Aykaç Kongar; Ferhan Özşeker
Journal:  Turk Thorac J       Date:  2015-10-01

2.  Chronic eosinophilic pneumonia: a paediatric case.

Authors:  Davide Tassinari; Chiara Di Silverio Carulli; Francesca Visciotti; Roberta Petrucci
Journal:  BMJ Case Rep       Date:  2013-04-25

3.  Successful treatment of acute relapse of chronic eosinophilic pneumonia with benralizumab and without corticosteroids: A case report.

Authors:  Shimon Izhakian; Barak Pertzov; Dror Rosengarten; Mordechai R Kramer
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

Review 4.  Eosinophilic pneumonias.

Authors:  Praveen Akuthota; Peter F Weller
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

5.  Asthmatic adult with marked blood eosinophilia: is it truly asthma?

Authors:  Shera Tan; Angela Takano; Aloysius Ho; Keng Leong Tan
Journal:  BMJ Case Rep       Date:  2018-05-07

6.  Anti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series.

Authors:  Hiroki Tashiro; Koichiro Takahashi; Yuki Kurihara; Hironori Sadamatsu; Yuki Kuwahara; Shinya Kimura; Naoko Sueoka-Aragane
Journal:  J Asthma Allergy       Date:  2022-02-09

7.  [Idiopathic chronic eosinophilic pneumonia - a diagnostic challenge].

Authors:  Ertunc Altiok; Rolf Kemper; Joachim Kindler
Journal:  Med Klin (Munich)       Date:  2009-07-18

8.  Significance of fractional exhaled nitric oxide in chronic eosinophilic pneumonia: a retrospective cohort study.

Authors:  Ji Young Park; Taehoon Lee; Hongyeul Lee; Yeon Joo Lee; Jong Sun Park; Young-Jae Cho; Ho Il Yoon; Jae Ho Lee; Choon-Taek Lee
Journal:  BMC Pulm Med       Date:  2014-05-12       Impact factor: 3.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.